Pharmaceutical segment

Johnson & Johnson’s (JNJ) Pharmaceutical segment includes immunology products, cardiovascular and metabolic products, infectious disease products, oncology products, neuroscience products, and pulmonary hypertension products.

Johnson & Johnson’s Pharmaceutical Segment: 4Q17 Estimates

The above chart compares revenues for the Pharmaceutical segment over the last eight quarters.

Immunology franchise

The immunology franchise includes the drugs Remicade, Stelara, and Simponi/Simponi Aria. For 4Q17, revenues for the franchise are expected to increase due to the strong performance of Stelara in both US and international markets, while Remicade and Simponi/Simponi Aria are expected to report lower sales due to competition and substantially offset growth.

Cardiovascular and metabolics franchise

The cardiovascular and metabolics franchise includes the drugs Invokana, Procrit, and Xarelto. Xarelto is expected to report growth following strong demand in the US markets, while Invokana and Procrit are expected to offset that growth.

Infectious diseases franchise

The infectious diseases franchise includes Hepatitis C products and HIV (human immunodeficiency virus) products. For 4Q17, the franchise is expected to decline due to lower sales of HIV product Prezcobix and Hepatitis C products Olysio, Invico, and Sovraid, partially offset by the strong performance of Edurant.

Oncology franchise

The oncology franchise includes the drugs Imbruvica, Zytiga, and Darzalex. For 4Q17, increased sales of Imbruvica and Darzalex are expected to drive growth in revenues, while lower sales of Zytiga are expected to partially offset that growth.

Neuroscience franchise

The neuroscience franchise includes the drugs Concerta, Xeplion, and Invega Sustenna. The franchise’s revenues are expected to report growth in 4Q17 due to increased sales of Invega Sustenna and Concerta, partially offset by other products.

Pulmonary hypertension

The pulmonary hypertension franchise was added to Johnson & Johnson’s portfolio as a result of the Actelion acquisition completed in June 2017.

The Vanguard Health Care ETF (VHT) holds 10.2% of its total investments in Johnson & Johnson (JNJ), 5.9% in Pfizer (PFE), 4.2% in AbbVie (ABBV), and 2.7% in Bristol-Myers Squibb (BMY).

Latest articles

Today, Canopy Growth announced that it acquired the Saskatchewan-based KeyLeaf Life Sciences along with entities relating to the company and its intellectual property. Here's what you need to know about the completed deal.

Yesterday, Tyson Foods (TSN) and fellow meat producers Pilgrim’s Pride (PPC) and Sanderson Farms (SAFM) took a hit to their stocks after news came out about an investigation over price-fixing allegations.

On June 24, RH (RH) was trading at $115.01, implying a rise of 21.2% since its announcement of its first-quarter earnings results on June 12. Despite the surge in its stock price, the company is still trading at a discount of 29.1% to its 52-week high.

26 Jun

Roku Stock Fell Close to 7.0% Yesterday

WRITTEN BY Aditya Raghunath

Roku stock fell 6.8% yesterday to close trading at $93.25 per share. Roku stock has lost over 9.0% in market value in the last two trading days. Prior to this pullback, Roku stock was up a whopping 235.0% year-to-date.

26 Jun

Beyond Meat Stock Up Today on New Product Launch

WRITTEN BY Rajiv Nanjapla

Today, Beyond Meat (BYND) announced that its new product, Beyond Beef, will hit markets across the US later this week.

FedEx (FDX) ended fiscal 2019 on a dismal note and reported a significant YoY decline in fourth-quarter earnings. The delivery giant posted adjusted EPS of $5.01, which was 15.2% lower than the year-ago quarter’s earnings of $5.91. The company cited sluggish revenue growth and increased expenses as the main reason behind the dismal bottom-line performance.